Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.51 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.51 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.51 |
| ▸ | ATG7 | O95352 | 7/20 | 0.50 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | YES1 | P07947 | 1/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | GAPDH | P04406 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20141608 | 0.91 | MEN1 (0.54) | HRASMEN1USP2POLBKMT2A | |
| SCHEMBL22758827 | 0.90 | MEN1 (0.54) | HRASMEN1USP2POLBKMT2A | |
| SCHEMBL20142633 | 0.90 | ATG7 (0.53) | HRASMEN1USP2POLBKMT2A | |
| SCHEMBL20141958 | 0.90 | ATG7 (0.53) | HRASMEN1USP2POLBKMT2A | |
| SCHEMBL22778899 | 0.90 | SRC (0.54) | HRASMEN1USP2POLBKMT2A | |
| SCHEMBL20141646 | 0.88 | ATG7 (0.53) | HRASMEN1USP2POLBKMT2A | |
| SCHEMBL20142000 | 0.88 | MEN1 (0.49) | HRASMEN1USP2POLBKMT2A | |
| SCHEMBL20141777 | 0.87 | MTOR (0.52) | HRASMEN1USP2POLBKMT2A | |
| SCHEMBL20142549 | 0.87 | ATG7 (0.54) | HRASMEN1USP2POLBKMT2A | |
| SCHEMBL20141743 | 0.86 | ATG7 (0.60) | HRASMEN1USP2POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865208-B2 | ATG7 inhibitors and the uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| WO-2018089786-A1 | ATG7 INHIBITORS AND THE USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865208-B2 | ATG7 inhibitors and the uses thereof | ATG7, BECN1, SQSTM1 | HRAS 25/4885MEN1 2795/4885USP2 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.